Corneal Edema Clinical Trial
Official title:
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
NCT number | NCT05626478 |
Other study ID # | AVC-003 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | June 1, 2023 |
Est. completion date | June 1, 2024 |
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
Status | Recruiting |
Enrollment | 100 |
Est. completion date | June 1, 2024 |
Est. primary completion date | June 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosed with clinically significant cataract and are planning to undergo non-complicated Clear Cornea Incision Cataract Extraction with Posterior Capsule IntraOcular Lens in one or both eyes - Are willing and able to comply with clinic visits and study related procedures - Are willing and able to sign the informed consent form Exclusion Criteria: - Under the age of 18 at the time of signing the Informed Consent Form - Pregnant or planning to become pregnant during the trial period - Have visual acuity potential of less than 20/30 as recorded by a Retinal Acuity Meter or Potential Acuity Meter glare testing - Have active infectious systemic disease - Have active infectious ocular or extraocular disease - Have punctal plug in the study eye - Have obstructed nasolacrimal duct in the study eye(s) (dacryocystitus) - Have known hypersensitivity to dexamethasone or are a known steroid responder - Have a history of ocular inflammation or macular edema - Has history of Laser Vision Correction (LASIK, PhotoRefractive Keratectomy) in the operated eye - Are currently being treated with immunomodulating agents in the study eye - Are currently being treated with immunosuppressants and/or oral steroids - Are currently being treated with corticosteroid implant (i.e Ozurdex) - Have a history of herpes simplex virus keratitis or present active bacterial, viral, or fungal keratitis in either eye - Have a history of complete punctal occlusion in one or both punctum - Currently using topical ophthalmic steroid medications - Are unwilling or unable to comply with the study protocol - Are determined by the Investigator to not be included for reasons not already specified (e.g., systemic, behavioral, or other ocular disease/abnormality) if the health of the subject or the validity of the study outcomes may be compromised by the subject's enrollment |
Country | Name | City | State |
---|---|---|---|
United States | Advanced Vision Care | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Nicole Fram M.D. |
United States,
Greenwood MD, Gorham RA, Boever KR. A Randomized Fellow-Eye Clinical Trial to Evaluate Patient Preference for Dexamethasone Intracanalicular Insert or Topical Prednisolone Acetate for Control of Postoperative Symptoms Following Bilateral Femtosecond Laser in Site Keratomileusis (LASIK). Clin Ophthalmol. 2020 Aug 6;14:2223-2228. doi: 10.2147/OPTH.S265311. eCollection 2020. — View Citation
Tyson SL, Bafna S, Gira JP, Goldberg DF, Jones JJ, Jones MP, Kim JK, Martel JM, Nordlund ML, Piovanetti-Perez IK, Singh IP, Metzinger JL, Mulani D, Sane S, Talamo JH, Goldstein MH; Dextenza Study Group. Multicenter randomized phase 3 study of a sustained-release intracanalicular dexamethasone insert for treatment of ocular inflammation and pain after cataract surgery. J Cataract Refract Surg. 2019 Feb;45(2):204-212. doi: 10.1016/j.jcrs.2018.09.023. Epub 2018 Oct 24. Erratum In: J Cataract Refract Surg. 2019 Jun;45(6):895. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Safety endpoint: corneal or retinal edema | Measured by slit lamp examination and supporting imaging and testing such as Pachymetry measured in micrometer (µm) or Macular (Optical Coherence Tomography) | Assessed throughout 90-day study period | |
Other | Safety endpoint: Signs of Rebound Iritis | Measured by slit lamp examination and scored by SUN (Standardization on Uveitis Nomenclature) grading scale: absence of cell to be defined as a grade of 0-0.5 and absence of flare to be defined as a grade of: 0-1, (0-4 score scale) higher scores (4) mean a worse outcome. (specifically sub-grouped Blue vs. Brown eyed subjects) | Assessed throughout 90-day study period | |
Other | Safety endpoint: Change in IOP (IntraOcular Pressure) initiating rescue medications | Measured by Applanation in millimeter Hg(Mercury), higher then 22mm Hg or lower then 10mm Hg mean a worse outcome and a need for rescue. | Assessed throughout 90-day study period | |
Primary | Mean change in anterior chamber inflammation (Cell and Flare) scores | Measured by SUN (Standardization on Uveitis Nomenclature) grading scale: absence of cell to be defined as a grade of 0-0.5 and absence of flare to be defined as a grade of: 0-1. 0-4 score scale, higher scores (4) mean a worse outcome. | Assessed on Days 1,7,30,90 | |
Primary | Mean change in pain score | Measured with the visual analog scale (VAS); between 0 and 100; 0 meaning no pain and 100 meaning worst pain possible | Assessed on Day 1,7, 30 and 90 | |
Secondary | Visual outcome (Best Corrected Visual Acuity) | Measured by ETDRS (Early Treatment Diabetic Retinopathy Study) chart. 0-70 letter read score. higher scores mean a better outcome. | Assessed on Day 1,7, 30 and 90 | |
Secondary | Absence of CME (Cystoid Macular Edema) | Measured by OCT (Optical Coherence Tomography) | Assessed on Day 90 | |
Secondary | Mean change in corneal staining | measured by the National Eye Institute 0-4 score scale, higher scores (4) mean a worse outcome. | Assessed on Day 7, 30 and 90 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05139771 -
EndoArt® Implantation in Subjects With Chronic Corneal Edema
|
N/A | |
Enrolling by invitation |
NCT05956535 -
Air Optix® Night and Day® Aqua Therapeutic Wear
|
||
Completed |
NCT02332109 -
ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy
|
N/A | |
Completed |
NCT04498169 -
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy
|
Phase 2 | |
Active, not recruiting |
NCT06041256 -
A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)
|
Phase 1/Phase 2 | |
Completed |
NCT04521140 -
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery
|
Phase 4 | |
Completed |
NCT05136443 -
Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
|
Phase 4 | |
Completed |
NCT01998568 -
The Intraocular Pressure Measured by Different Tonometers in Corneal Edema
|
N/A | |
Recruiting |
NCT04191629 -
Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema
|
Phase 1 | |
Completed |
NCT04975971 -
A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery
|
||
Completed |
NCT05309135 -
A Safety and Efficacy Study of Corneal Injection for Endothelial Dysfunction Using Human Corneal Endothelial Cell Therapy in Subjects With Corneal Edema Secondary to Endothelial Dysfunction
|
Phase 1 | |
Completed |
NCT01853696 -
Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty
|
Phase 4 | |
Completed |
NCT01244334 -
Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.
|
Phase 4 | |
Completed |
NCT05891106 -
AONDA Therapeutic Indication Study I
|
||
Active, not recruiting |
NCT04894110 -
Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
|
Phase 1 | |
Completed |
NCT01387620 -
Comparison of DisCoVisc and Hydroxypropylmethylcellulose 2%
|
Phase 4 | |
Completed |
NCT00346138 -
A Comparison Between Full Thickness and Partial Thickness Corneal Transplantation for Corneal Edema
|
N/A | |
Completed |
NCT05271058 -
Effect of Intracameral Steroids During Phacoemulsification on the Cornea
|
Phase 3 | |
Completed |
NCT01890252 -
Hyper-CL™ Lens (Hyper Osmotic Contact Lens) In Subjects Suffering From Corneal Edema
|
N/A | |
Not yet recruiting |
NCT00800423 -
Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema
|
Phase 3 |